NCT05147467Phase 2Recruiting

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Study sponsor: Ascentage Pharma Group Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants75Estimated

Source updated2026-03-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-27 · 1 field changed

Primary completion date changed

− Before

~~Sep 2024~~

+ After

Dec 2026

Check registry source

Study details

Conditions studied

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Treatments or interventions studied

APG2575Drug

Primary outcomes · main study measures

Read the study measures

measure: Objective Response Rate (ORR); description: ORR is defined by Complete Remission (CR)+ CR with incomplete marrow recovery (CRi) + Partial Remission (PR) (according to NCI-WG CLL(2018)) and by CR+PR ( according to Lugano (2014)).Response will be evaluated every 2 cycles (8 weeks) till complete treatment or one month after last dose.; timeFrame: Up to 9 months after the last subject enrolled.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history